LGND:NASDAQ
Ligand Pharmaceuticals Inc
291,56 USD
arrow_downward
−0,58%(−1,70) 1D
8. lis, 14:25:32 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za LGND...
Otvori
290,41 USD
Najviša
292,42 USD
Najniža
281,74 USD
Trž. kap.
5,81 mlr.
Prosj. kol.
241,66 tis.
Količina
132,22 tis.
P/E omjer
31,01
52-tjed. najviša
326,63 USD
52-tjed. najniža
175,89 USD
EPS
9,40 USD
Beta
1,06
Dionice u optjecaju
19,94 mil.
Broj djelatnika
47
Otvori
290,41 USD
Najviša
292,42 USD
Najniža
281,74 USD
Trž. kap.
5,81 mlr.
Prosj. kol.
241,66 tis.
Količina
132,22 tis.
P/E omjer
31,01
52-tjed. najviša
326,63 USD
52-tjed. najniža
175,89 USD
EPS
9,40 USD
Beta
1,06
Dionice u optjecaju
19,94 mil.
Broj djelatnika
47
Vijesti
Iz web-izvora i od partnera za vijesti
Yahoo Finance
·
prije 16 sati
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
Benzinga
·
prije 1 dan
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
AD HOC NEWS
·
prije 1 dan
Ligand Pharmaceuticals stock fell 3.2 percent as insiders sold shares
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc – informacije
Glavni izvršni direktor-
Zaposlenici47
Osnovanoruj 1987
SjedišteJupiter, Florida, Sjedinjene Američke Države
Sektor-
Web-lokacijaligand.com